Histone deacetylase inhibitors in multiple myeloma | Zendy

Sarah Deleu | Zendy; Eline Menu | Zendy; Els Van Valckenborgh | Zendy; Ben Van Camp | Zendy; Joanna Fraczek | Zendy; Isabelle Vande Broek | Zendy; Vera Rogiers | Zendy; Karin Vanderkerken | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Histone deacetylase inhibitors in multiple myeloma

Author(s) -

Sarah Deleu,

Eline Menu,

Els Van Valckenborgh,

Ben Van Camp,

Joanna Fraczek,

Isabelle Vande Broek,

Vera Rogiers,

Karin Vanderkerken

Publication year - 2009

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2009.e9

Subject(s) - bortezomib , multiple myeloma , medicine , cancer research , histone deacetylase , bone marrow , histone , lenalidomide , in vivo , pharmacology , immunology , biology , microbiology and biotechnology , genetics , gene

Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research